ALZN Alzamend Neuro Inc
Company Analysis
Latest News
🟢 Alzamend Neuro is trading 5% up today with no confirmed new catalyst
Alzamend Neuro is trading 5.2% up at $1.82; no confirmed new company-specific announcement explains the move. - A previously announced Phase 1/2A...
🟢 Alzamend Neuro is trading 11.3% up in pre-market with no confirmed company-specific catalyst
Alzamend Neuro is trading at $1.93, up 11.30%, in pre-market, with no confirmed company-specific catalyst found. - The company previously announced Phase 1/2A...
🟢 Alzamend Neuro is trading 5.8% up in after-hours trading with immediate catalyst unclear
Alzamend Neuro is trading at $1.83 (+5.78%) in after-hours trading, with no confirmed catalyst identified for the rise. - The company announced August 18 an...
Alzamend Neuro regains Nasdaq compliance, exceeding equity requirements
Alzamend Neuro, Inc. announced on September 16, 2026, that it regained compliance with Nasdaq Stock Market requirements. Nasdaq issued a formal notification...
🔴 Alzamend Neuro is trading 6.74% down in pre-market after missing EPS estimates
Alzamend Neuro is trading 6.74% down at $1.66 after reporting first-quarter fiscal 2027 EPS of $(0.68), missing the $(0.56) consensus estimate by 21.43%. -...
🔴 Alzamend Neuro is trading 6.47% down today after a filing disclosed $3.027 million net loss
Alzamend Neuro is trading at $1.59 (-6.47%) after its September 10, 2026 Form 10-Q disclosed a $3.027 million net loss and no product revenue. - The filing...
🔴 Alzamend Neuro is trading 6.47% down in after-hours trading after filing a quarterly report raising going-concern doubts
Alzamend Neuro is trading 6.47% down at $1.59 in after-hours trading after filing its September 10, 2026 Form 10-Q for the quarter ended July 31, 2026. - The...
🔴 Alzamend Neuro is trading 7.12% down in after-hours trading ahead of expected September 9 earnings
Alzamend Neuro is trading 7.12% down at $1.56 in after-hours trading after closing at $1.68 on September 8, 2026, as investors may be positioning cautiously...
Alzamend Neuro Inc Q3 2026 Earnings Preview: What Analysts Expect on September 09, 2026
Alzamend Neuro is expected to report a consensus EPS of -$0.56 on zero revenue for the quarter ending July 31, 2026, as the stock currently trades at $1.67,...
🟢 Alzamend Neuro is trading 8% up in pre-market; catalyst remains unclear
Alzamend Neuro is trading 8.24% up at $1.84 with no clearly identifiable company-specific catalyst on September 3, 2026. - A September 3 report highlighted...
🔴 Alzamend Neuro is trading 5.15% down today with no clear company-specific catalyst
Alzamend Neuro is trading 5.15% down now at $1.56, reversing the prior session’s gain; the catalyst remains unclear. - No September 2, 2026 company-specific...
🟢 Alzamend Neuro is trading 5.66% up today despite an unclear catalyst
Alzamend Neuro is trading 5.66% up at $1.68, despite no identified company-specific announcement explaining the September 1, 2026 rise. - Recent company news...
🟢 Alzamend Neuro is trading 6.92% up in pre-market as catalyst remains unclear
Alzamend Neuro is trading at $1.70, up 6.92% in pre-market, with no identified company-specific announcement explaining the September 1, 2026 rise. - Latest...
🔴 Alzamend Neuro is trading 6.78% down today
Alzamend Neuro is trading 6.78% down at $1.55 after falling from its August 28, 2026 close of $1.66; no company-specific announcement explaining the August 31...
🔴 Alzamend Neuro is trading 15.61% down in pre-market after S-1 registration for up to 98,388,305 shares
Alzamend Neuro is trading 15.61% down now at $1.35 after investors reacted to an August 21, 2026 Form S-1 registration for Ault Lending’s resale of up to...
🔴 Alzamend Neuro is trading 6.86% down in pre-market amid dilution concerns
Alzamend Neuro is trading 6.86% down at $1.49, likely under pressure from dilution concerns tied to an August 21 registration filing. - The filing covers...
🔴 Alzamend Neuro is trading 6.2% down in after-hours trading amid possible dilution overhang
Alzamend Neuro is trading 6.2% down at $1.50 in after-hours trading, with potential resale shares issuable upon preferred-stock conversion creating a possible...
🟢 Alzamend Neuro is trading 6% up today amid broad biotech-sector strength
Alzamend Neuro is trading 6% up at $1.65, primarily supported by broad biotech-sector strength as XBI gains 2.06% during the August 25, 2026 session. - No new...
🔴 Alzamend Neuro is trading 6.41% down today after filing a 98.4 million-share resale registration
Alzamend Neuro is trading 6.41% down at $1.46 after filing a registration statement covering the resale of up to 98,388,305 common shares. - The shares may be...
Alzamend Neuro's Massive Share Offering Dwarfs Its Tiny Market Cap — Can the Stock Absorb the Blow?
Shares of Alzamend Neuro (ALZN) slid 7.1% to $1.45 on August 24, extending a volatile week after the clinical-stage biotech disclosed a shelf registration...